Clinical trials: Pancreatic Cancer Stage
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer
In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable or borderline resectable locally advanced pancreatic cancer combined with chemotherapy…
- Trial name
- PROTACT (NCT01676259)
- Testing
- siG12D-LODER, Gemcitabine+nab-Paclitaxel, Folfirinox
- Where
- 9 sites in United States, Israel
- Volunteers
- 80 people
- Sponsor
- Silenseed Ltd
Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial
This phase II trial compares the effect of combination therapy with capecitabine and temozolomide to lutetium Lu 177 dotatate for the treatment of pancreatic neuroendocrine tumors that have spread to other parts of the body…
- Trial name
- NCT05247905
- Testing
- Lutetium Lu 177 Dotatate, Capecitabine, Temozolomide
- Where
- 171 sites in United States
- Volunteers
- 31 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Solid Tumor, Gastric Cancer
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05156866
- Testing
- TORL-2-307-ADC
- Where
- 12 sites in United States, South Korea
- Volunteers
- 163 people
- Sponsor
- TORL Biotherapeutics, LLC
Colorectal Cancer, Esophageal Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer
RATIONALE: LMB-9 immunotoxin can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced pancreatic, esophageal, stomach, colon or rectal cancer.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT00010270
- Testing
- LMB-9 immunotoxin
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Freiburg
Cancer, Pancreatic Cancer
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
The objectives of this study are: To determine the safety and MTD of CPI-613, when used in combination with Gemcitabine, in cancer patients. To compare the safety and efficacy of CPI-613/Gemcitabine combination vs.
- Conditions
- Cancer, Pancreatic Cancer, Pancreatic Carcinoma
- Trial name
- NCT00907166
- Testing
- CPI-613, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Cornerstone Pharmaceuticals
Pancreatic Cancer
Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
The purpose of the study is to determine the optimal safe and tolerable dose of gemcitabine in combination with once daily or twice daily dose of PTK/ZK in patients with unresectable pancreatic cancer.
- Trial name
- NCT00185588
- Testing
- Vatalanib, Gemcitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- George Albert Fisher
Adenocarcinoma, Pancreatic Neoplasms
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
The purpose of this study is to evaluate the clinical activity of gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan (GAX-CI) in patients with metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma, Pancreatic Neoplasms, Neoplasm, Glandular, Neoplasms
- Trial name
- NCT03535727
- Testing
- Nab-paclitaxel, Gemcitabine, Capecitabine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Solid Tumors
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced solid tumors. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and…
- Trial name
- NCT01302405
- Testing
- PRI-724
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Prism Pharma Co., Ltd.
Pancreatic Ductal Adenocarcinoma
Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer
Patients with metastatic, locally advanced, or unresectable pancreatic ductal carcinomas (PDA) who have failed prior chemotherapy with gemcitabine regimens have an extremely poor prognosis with progression-free survival of around…
- Trial name
- NCT01580397
- Testing
- INNO-206
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- ImmunityBio, Inc.
Pancreatic Cancer
Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1
This study is to investigate whether neoadjuvant chemotherapy plus SBRT results in better outcomes compared with neoadjuvant chemotherapy alone and also compare the efficacy of gemcitabine plus nab-paclitaxel with SBRT and S-1…
- Trial name
- BRPCNCC-1 (NCT03777462)
- Testing
- Neoadjuvant gemcitabine plus nab-paclitaxel, Neoadjuvant gemcitabine plus nab-paclitaxel with SBRT, Neoadjuvant S-1 plus nab-paclitaxel with SBRT
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Changhai Hospital
Pancreatic Cancer
A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients
The investigators hypothesize that the combination of the FOLFIRINOX regimen (a combination of 5-fluorouracil, irinotecan and oxaliplatin chemotherapy) to provide maximal systemic disease control and FDR-gemcitabine chemotherapy…
- Trial name
- NCT01661088
- Testing
- FOLFIRINOX, Intensity-modulated radiotherapy (IMRT), Surgical Exploration
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Michigan Rogel Cancer Center
Pancreatic Cancer
Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
The primary objective is to determine the maximum tolerated dose (MTD) of azacitidine and gemcitabine in subjects with previously untreated and unresectable pancreatic cancer.
- Trial name
- NCT01167816
- Testing
- Vidaza
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Oklahoma
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
This phase I trial is studying the side effects and best dose of erlotinib when given together with gemcitabine and radiation therapy in treating patients with locally advanced unresectable pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00063947
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride, radiation therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas
RATIONALE: Surgery to remove the pancreas, some of the small intestine, and lymph nodes may be more effective treatment for cancer of the pancreas than surgery to remove the pancreas and some of the small intestine alone.
- Trial name
- NCT00003049
- Testing
- fluorouracil, leucovorin calcium, conventional surgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Solid Tumor, Breast Cancer
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
This proposed Phase I clinical trial of SON-DP is an FIH, open-label, Phase Ia/Ib dose escalation and expansion study to evaluate the safety, tolerability, PK, and PD of SON-DP in participants with relapsed/refractory/intolerant…
- Conditions
- Solid Tumor, Breast Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT05989724
- Testing
- SON-DP
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Qurgen Inc.
Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
The purpose of this study is to evaluate the efficacy of thalidomide on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.
- Trial name
- PTCA199-5 (NCT06017284)
- Testing
- Thalidomide, Nab paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
CEND-1, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT03517176
- Testing
- CEND-1, Nab-paclitaxel, Gemcitabine
- Where
- 3 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Lisata Therapeutics, Inc.
Pancreatic Cancer, Locally Advanced Pancreatic Cancer
Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Safety and Feasibility Study
This is a single-arm, phase I clinical study designed to evaluate the safety and feasibility of SCART (Stereotactic Centralized Ablative Radiation Therapy) dose escalation in patients with locally advanced pancreatic cancer.
- Trial name
- SCART-P (NCT07173374)
- Testing
- SCART Dose Escalation Arm
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shandong Cancer Hospital and Institute
Pancreatic Cancer
Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma
This is an open-label phase 1-b study to evaluate the safety and efficacy of CCX872-B in patients with pancreatic adenocarcinoma also receiving FOLFIRINOX chemotherapy.
- Trial name
- NCT02345408
- Testing
- CCX872-B
- Where
- 6 sites in United States, Netherlands
- Volunteers
- 54 people
- Sponsor
- Amgen
Pancreatic Neoplasms
Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer
The trial is conducted in order to evaluate the efficacy, safety and pharmacokinetics of BI 2536 in the treatment of unresectable advanced pancreatic cancer as first line or second line therapy.
- Trial name
- NCT00710710
- Testing
- BI 2536
- Where
- 10 sites in Austria, Germany
- Volunteers
- 89 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.